Moreover, TRPML1 activated the BDNF/TrkB signaling pathway and interacted with the p62-dependent dynein to attenuate NAD in AD (Figure 7), providing new insights into understanding pathology and potential therapeutic targets for AD. The gene discussed is NTRK2; the disease is Alzheimer disease.